Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer

Cancer Research

Volumn 74, Issue 1, 2014, Pages 31-37

  Steffen, Jamin D ^a   Tholey, Renee M ^a   Langelier, Marie France ^a   Planck, Jamie L ^a   Schiewer, Matthew J ^a   Lal, Shruti ^a   Bildzukewicz, Nikolai A ^a   Yeo, Charles J ^a   Knudsen, Karen E ^a   Brody, Jonathan R ^a   Pascal, John M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PLATINUM;

ALLOSTERISM; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; PROTEIN TARGETING; TRANSCRIPTION REGULATION;

ALLOSTERIC REGULATION; ANIMALS; CLONING, MOLECULAR; DNA DAMAGE; HELA CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; MUTAGENESIS; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN STRUCTURE, TERTIARY; TRANSFECTION;

EID: 84892696097     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1701     Document Type: Article

References (27)

1. Hassa PO, Hottiger MO. The diverse biological roles of mammalian PARPs, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci 2008;13:3046-82.
2. Lowery MA, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, Ludwig E, et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist 2011;16:1397-402.
3. Langelier MF, Planck JL, Roy S, Pascal JM. Crystal structures of poly (ADP-ribose) polymerase-1 (PARP-1) zinc fingers bound to DNA: structural and functional insights into DNA-dependent PARP-1 activity. J Biol Chem 2011;286:10690-701.
4. Langelier MF, Servent KM, Rogers EE, Pascal JM. A third zinc-binding domain of human poly(ADP-ribose) polymerase-1 coordinates DNAdependent enzyme activation. J Biol Chem 2008;283:4105-14.
5. Langelier MF, Ruhl DD, Planck JL, Kraus WL, Pascal JM. The Zn3 domain of human poly(ADP-ribose) polymerase-1 (PARP-1) functions in both DNA-dependent poly(ADP-ribose) synthesis activity and chromatin compaction. J Biol Chem 2010;285:18877-8.
6. Altmeyer M, Messner S, Hassa PO, Fey M, Hottiger MO. Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites. Nucleic Acids Res 2009;37:3723-38.
7. Langelier MF, Planck JL, Roy S, Pascal JM. Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science 2012;336:728-32.
8. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl) ation reactions in the regulation of nuclear functions. Biochem J 1999;342:249-68.
9. Alvarez-Gonzalez R, Althaus FR. Poly(ADP-ribose) catabolism in mammalian cells exposed to DNA-damaging agents. Mutat Res 1989; 218:67-74.
10. Malanga M, Althaus FR. The role of poly(ADP-ribose) in the DNA damage signaling network. Biochem Cell Biol 2005;83:354-6.
11. Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer 2011;105:1114-22.
12. Ferraris DV. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. from concept to clinic. J Med Chem 2010;53:4561-84.
13. Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, Thorsell A, et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol 2012;30:283-8.
14. Langelier MF, Planck JL, Servent KM, Pascal JM. Purification of human PARP-1 and PARP-1 domains from Escherichia coli for structural and biochemical analysis. Methods Mol Biol 2011;780:209-26.
15. Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov 2012;2:1134-49.
16. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinicalPARPinhibitors. Cancer Res 2012;72:5588-99.
17. Pishvaian MJ, Wang H, Zhuang T, He AR, Hwang JJ, Hankin A, et al. A phase I/II study of ABT-888 in combination with 5-fluorouracil (5-FU) and oxaliplatin (ox) in patients with metastatic pancreatic cancer (MPC). J Clin Oncol 30, 2012 (suppl 34; abstr 147).
18. Jacob DA, Bahra M, Langrehr JM, Boas-Knoop S, Stefaniak R, Davis J, et al. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells. J Gastroenterol Hepatol 2007;22:738-48.
19. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007;13:2728-37.
20. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008;105:17079-84.
21. Olaussen KA, Adam J, Vanhecke E, Vielh P, Pirker R, Friboulet L, et al. PARP1 impact on DNA repair of platinum adducts: Preclinical and clinical read-outs. Lung Cancer 2013;80:216-22.
22. Guggenheim ER, Ondrus AE, Movassaghi M, Lippard SJ. Poly(ADPribose) polymerase-1 activity facilitates the dissociation of nuclear proteins from platinum-modified DNA. Bioorg Med Chem 2008;16: 10121-8.
23. Zhu G, Chang P, Lippard SJ. Recognition of platinum-DNA damage by poly(ADP-ribose) polymerase-1. Biochemistry 2010;49:6177-83.
24. Kraus WL. Transcriptional control by PARP-1: Chromatin modulation, enhancer-binding, coregulation, and insulation. Curr Opin Cell Biol 2008;20:294-302.
25. Welsby I, Hutin D, Leo O. Complex roles of members of the ADP-ribosyl transferase super family in immune defences: looking beyond PARP1. Biochem Pharmacol 2012;84:11-20.
26. Ghoreschi K, Laurence A, O'Shea JJ. Selectivity and therapeutic inhibition of kinases: To be or not to be? Nat Immunol 2009;10:356-360.
27. van der Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC, Swartz MJ, et al. In vivo therapeutic responses contingent on fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 2005; 11:7508-15.